Convatec responds to CMS’s revised payment rate for skin substitutes
By HME News Staff
Updated 8:55 AM CST, Tue November 4, 2025
LONDON – Convatec says CMS’s revised payment rate for skin substitutes represents an estimated headwind of about 1% to 2% of Group revenue for 2026. That is unchanged from the company’s guidance from the first half of 2025. CMS announced Oct. 31 that it plans to pay $127.28 per sq cm for skin substitutes starting Jan. 1, 2026. Convatec makes InnovaMatrix, a placental-derived, FDA-cleared medical device for wound management, including pressure, venous, diabetic, and surgical wounds. “We are confident of delivering long term profitable growth from InnovaMatrix, including developing sales and securing coverage across a range of indications, both within and outside the United States,” the company stated. Convatec says InnovaMatrix is highly effective, with significant health benefits to patients and health care professionals. It also says it recently submitted further real-world evidence (RWE) to CMS on the device, in addition to evidence published in December 2024. The company has a target date for publishing randomized controlled trials in 2026.
- Go here to read Convatec’s statement in response to CMS’s draft payment proposal for skin substitutes.
Comments